Sign in or Register   Sign in or Register
  |  

Human Anti-ICOS Recombinant Antibody (CBXC-0734) (CBMAB-C1848-CQ)

This product is a recombinant human antibody that recognizes ICOS. The antibody CBXC-0734 can be used for immunoassay techniques such as: FC.
See all ICOS antibodies

Summary

Host Animal
Human
Specificity
Human, Mouse, Rat
Clone
CBXC-0734
Antibody Isotype
IgG1
Application
FC

Basic Information

Specificity
Human, Mouse, Rat
Antibody Isotype
IgG1
Clonality
Monoclonal
Application Notes
The COA includes recommended starting dilutions, optimal dilutions should be determined by the end user.

Formulations & Storage [For reference only, actual COA shall prevail!]

Format
Liquid
Buffer
Buffer containing stabilizer
Preservative
0.05% sodium azide
Storage
Store at +4°C short term (1-2 weeks). Aliquot and store at -20°C long term. Avoid repeated freeze/thaw cycles.

Target

Full Name
Inducible T Cell Costimulator
Introduction
The protein encoded by this gene belongs to the CD28 and CTLA-4 cell-surface receptor family. It forms homodimers and plays an important role in cell-cell signaling, immune responses, and regulation of cell proliferation.
Entrez Gene ID
Human29851
Mouse54167
Rat64545
UniProt ID
HumanQ9Y6W8
MouseQ9WVS0
RatQ9R1T7
Alternative Names
Inducible T Cell Costimulator
Function
Enhances all basic T-cell responses to a foreign antigen, namely proliferation, secretion of lymphokines, up-regulation of molecules that mediate cell-cell interaction, and effective help for antibody secretion by B-cells. Essential both for efficient interaction between T and B-cells and for normal antibody responses to T-cell dependent antigens. Does not up-regulate the production of interleukin-2, but superinduces the synthesis of interleukin-10. Prevents the apoptosis of pre-activated T-cells. Plays a critical role in CD40-mediated class switching of immunoglobin isotypes (By similarity).
Biological Process
Cell-cell adhesion Source: GO_Central
Immune response Source: UniProtKB
T cell costimulation Source: GO_Central
T cell tolerance induction Source: GO_Central
Cellular Location
Isoform 1: Cell membrane
Isoform 2: Secreted
Involvement in disease
Immunodeficiency, common variable, 1 (CVID1):
A primary immunodeficiency characterized by antibody deficiency, hypogammaglobulinemia, recurrent bacterial infections and an inability to mount an antibody response to antigen. The defect results from a failure of B-cell differentiation and impaired secretion of immunoglobulins; the numbers of circulating B-cells is usually in the normal range, but can be low.
Topology
Extracellular: 21-140
Helical: 141-161
Cytoplasmic: 162-199
PTM
N-glycosylated.

Chavez, J. C., Foss, F. M., William, B. M., Brammer, J. E., Smith, S. M., Prica, A., ... & Siu, L. L. (2023). Targeting the Inducible T-cell Costimulator (ICOS) in Patients with Relapsed/Refractory T-follicular Helper Phenotype Peripheral T-cell and Angioimmunoblastic T-cell Lymphoma. Clinical Cancer Research, 29(10), 1869-1878.

Boggio, E., Gigliotti, C. L., Moia, R., Scotta, A., Crespi, I., Boggione, P., ... & Dianzani, U. (2022). Inducible T‐cell co‐stimulator (ICOS) and ICOS ligand are novel players in the multiple‐myeloma microenvironment. British Journal of Haematology, 196(6), 1369-1380.

Di Raimondo, C., Rubio‐Gonzalez, B., Palmer, J., Weisenburger, D. D., Zain, J., Wu, X., ... & Querfeld, C. (2022). Expression of immune checkpoint molecules programmed death protein 1, programmed death‐ligand 1 and inducible T‐cell co‐stimulator in mycosis fungoides and Sézary syndrome: association with disease stage and clinical outcome. British Journal of Dermatology, 187(2), 234-243.

Ramavath, N. N., Gadipudi, L. L., Provera, A., Gigliotti, L. C., Boggio, E., Bozzola, C., ... & Sutti, S. (2021). Inducible T-cell costimulator mediates lymphocyte/macrophage interactions during liver repair. Frontiers in Immunology, 12, 786680.

Raineri, D., Cappellano, G., Vilardo, B., Maione, F., Clemente, N., Canciani, E., ... & Chiocchetti, A. (2021). Inducible T-cell costimulator ligand plays a dual role in melanoma metastasis upon binding to osteopontin or inducible T-cell costimulator. Biomedicines, 10(1), 51.

Solinas, C., Gu-Trantien, C., & Willard-Gallo, K. (2020). The rationale behind targeting the ICOS-ICOS ligand costimulatory pathway in cancer immunotherapy. ESMO open, 5(1), e000544.

Rischin, D., Groenland, S. L., Lim, A. M. L., Martin-Liberal, J., Moreno, V., Perez, J. T., ... & Angevin, E. (2019). Inducible T cell costimulatory (ICOS) receptor agonist, GSK3359609 (GSK609) alone and in combination with pembrolizumab (pembro): Preliminary results from INDUCE-1 expansion cohorts (EC) in head and neck squamous cell carcinoma (HNSCC). Annals of Oncology, 30, v454-v455.

Panneton, V., Chang, J., Witalis, M., Li, J., & Suh, W. K. (2019). Inducible T‐cell co‐stimulator: signaling mechanisms in T follicular helper cells and beyond. Immunological Reviews, 291(1), 91-103.

Zhang, M., Wu, Y., Bastian, D., Iamsawat, S., Chang, J., Daenthanasanmak, A., ... & Yu, X. Z. (2018). Inducible T-cell co-stimulator impacts chronic graft-versus-host disease by regulating both pathogenic and regulatory T cells. Frontiers in Immunology, 9, 1461.

Amatore, F., Gorvel, L., & Olive, D. (2018). Inducible Co-Stimulator (ICOS) as a potential therapeutic target for anti-cancer therapy. Expert opinion on therapeutic targets, 22(4), 343-351.

Ask a question We look forward to hearing from you.
0 reviews or Q&As
Loading...
Have you used Human Anti-ICOS Recombinant Antibody (CBXC-0734)?
Submit a review and get a Coupon or an Amazon gift card. 20% off Coupon $30 eGift Card
Submit a review
Loading...
For research use only. Not intended for any clinical use.

Custom Antibody Labeling

We also offer labeled antibodies developed using our catalog antibody products and nonfluorescent conjugates (HRP, AP, Biotin, etc.) or fluorescent conjugates (Alexa Fluor, FITC, TRITC, Rhodamine, Texas Red, R-PE, APC, Qdot Probes, Pacific Dyes, etc.).

Online Inquiry

Documents

Contact us

  • Tel: (USA)
  • (UK)
  • Fax:
  • Email:

Submit A Review

Go to
Compare